Array Biopharma Inc (NASDAQ:ARRY)
| 4.96 Data as of Jun 18 |  -0.13 / -2.55%Today’s Change | 3.16 Today|||52-Week Range 6.56 | +33.33% Year-to-Date |
Latest ARRY News | Press Releases
Today’s Trading
| Previous close | 5.09 |
| Today’s open | 5.10 |
| Day’s range | -- - -- |
| Volume | 1,168,187 |
| Average volume (3 months) | 1,430,283 |
| Market cap | $579.2M |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/18/2013
Growth & Valuation
| Earnings growth (last year) | +67.65% |
| Earnings growth (this year) | -66.67% |
| Earnings growth (next 5 years) | +16.00% |
| Revenue growth (last year) | +18.41% |
| P/E ratio | NM |
| Price/Sales | 2.88 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| OREXOrexigen Therapeutic... | +0.10 | +1.59% |
| SGNTSagent Pharmaceutica... | +0.08 | +0.41% |
| ICPTIntercept Pharmaceut... | +0.20 | +0.61% |
| NLNKNewLink Genetics Cor... | +0.32 | +1.50% |
Data as of 3:59pm ET, 06/18/2013
Financials
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $85.1M |
| Annual profit (last year) | -$23.6M |
| Net profit margin | -27.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
President & Chief Scientific Officer Kevin Koch, PhD |
Chief Executive Officer & Director Ron Squarer, MBA |
Corporate headquarters Boulder, Colorado |
Forecasts
